AstraZeneca funds independent medical education programs to improve awareness, diagnosis, and treatment knowledge of transthyretin amyloidosis for multidisciplinary healthcare professionals.
Independent Medical Education Grant for Transthyretin Amyloidosis supports educators providing clinician education on hereditary disease recognition, diagnosis, and treatment to improve patient care.
Responses to Requests for Proposals supports organizations delivering independent education for healthcare professionals and patients to address knowledge gaps and improve care in ATTR amyloidosis, AHP, and PH1.
Alnylam Pharmaceuticals' CME Grants fund independent, evidence-based education for healthcare professionals on ATTR amyloidosis, AHP, and PH1.
Educational Grants - Alnylam Pharmaceuticals support healthcare professionals and patients through independent education on three rare diseases to advance earlier diagnosis, treatment decisions, and disease management.
Clinical Fellowships for ATTR Amyloidosis supports institutional programs that train physicians in disease diagnosis, treatment, and research to improve early recognition and patient-centered care.